Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NUVB

NUVB - Nuvation Bio Inc. Stock Price, Fair Value and News

$5.30-0.31 (-5.53%)
Market Closed

25/100

NUVB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

25/100

NUVB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.47

Target 3M

$5.03

Target 6M

$4.75

NUVB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NUVB Price Action

Last 7 days

-13.8%

Last 30 days

-41.5%

Last 90 days

2.9%

Trailing 12 Months

116.3%

NUVB RSI Chart

NUVB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NUVB Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-8.35

Price/Sales (Trailing)

39.6

EV/EBITDA

-7.95

Price/Free Cashflow

-9.56

NUVB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.47

Target 3M

$5.03

Target 6M

$4.75

NUVB Fundamentals

NUVB Revenue

Revenue (TTM)

45.9M

Rev. Growth (Yr)

-18.11%

Rev. Growth (Qtr)

174.48%

NUVB Earnings

Earnings (TTM)

-217.5M

Earnings Growth (Yr)

-35.38%

Earnings Growth (Qtr)

5.45%

NUVB Profitability

Operating Margin

100.00%

EBT Margin

-473.98%

Return on Equity

-66.74%

Return on Assets

-36.15%

Free Cashflow Yield

-10.46%

NUVB Investor Care

Shares Dilution (1Y)

1.86%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202533.3M39.6M45.9M0
202426.8M27.8M27.4M27.1M
202311.5M16.7M21.1M24.6M
20223.5M3.5M4.8M7.4M
20211.9M2.1M2.5M3.0M
20201.5M1.6M1.8M1.9M
20190001.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Nuvation Bio Inc.

NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
 CEO
 WEBSITEnuvationbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES54

Nuvation Bio Inc. Frequently Asked Questions

NUVB is the stock ticker symbol of Nuvation Bio Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Nuvation Bio Inc. is 1.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NUVB's fair value in chart for subscribers.

The fair value guage provides a quick view whether NUVB is over valued or under valued. Whether Nuvation Bio Inc. is cheap or expensive depends on the assumptions which impact Nuvation Bio Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NUVB.

As of Wed Jan 28 2026, NUVB's PE ratio (Price to Earnings) is -8.35 and Price to Sales (PS) ratio is 39.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUVB PE ratio will change depending on the future growth rate expectations of investors.